Lead Product(s) : Pimicotinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Pimicotinib Improves Outcomes in Tenosynovial Giant Cell Tumor Trial
Details : ABSK021 (pimicotinib) is a novel, orally available, highly selective, and potent small molecule CSF-1R inhibitor. It is being evaluated for for the treatment of tenosynovial giant cell tumor.
Brand Name : ABSK021
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 11, 2024
Lead Product(s) : Pimicotinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pimicotinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Abbisko’s CSF-1R Inhibitor Pimicotinib Receives Orphan Drug Designation
Details : ABSK021 (pimicotinib) is a selective CSF-1R inhibitor currently in phase 3 studies for treating inoperable tenosynovial giant cell tumors.
Brand Name : ABSK021
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 08, 2024
Lead Product(s) : Pimicotinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pimicotinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ABSK021 (pimicotinib) is a novel, orally available, highly selective, and potent small molecule CSF-1R inhibitor. It is being evaluated for for the treatment of tenosynovial giant cell tumor (TGCT).
Brand Name : ABSK021
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 13, 2023
Lead Product(s) : Pimicotinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pimicotinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Merck Group
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Merck will receive an exclusive license to commercialize ABSK021 (pimicotinib), an oral, highly selective and potent small-molecule antagonist of colony stimulating factor-1 receptor, currently in Phase III for tenosynovial giant cel...
Brand Name : ABSK021
Molecule Type : Small molecule
Upfront Cash : $70.0 million
December 04, 2023
Lead Product(s) : Pimicotinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Merck Group
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?